Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Show other versions (1)

Bibliographic Details
Main Authors:	Ahai Luvai, Wycliffe Mbagaya, Alistair S. Hall, Julian H. Barth
Format:	Article
Language:	English
Published:	SAGE Publishing 2012-02-01
Series:	Clinical Medicine Insights: Cardiology
Online Access:	http://www.la-press.com/rosuvastatin-a-review-of-the-pharmacology-and-clinical-effectiveness-i-a3036

Similar Items

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
by: Ahai Luvai, et al.
Published: (2012-01-01)

ROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
by: A. E. Semenova, et al.
Published: (2018-06-01)

Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities
by: Marina G. Bubnova, et al.
Published: (2021-06-01)

Reducing cardiovascular risk: an emphasis on rosuvastatin
by: Anikin G.S., et al.
Published: (2017-11-01)

Lipoprotein(a): Insights for the Practicing Clinician
by: Pyotr Telyuk, et al.
Published: (2022-06-01)

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
by: Sydney B Long, et al.
Published: (2010-12-01)

Modern views on clinical and economical effectiveness of rosuvastatin
by: S. K. Zyryanov, et al.
Published: (2008-02-01)

THE CONCERNS OF ROSUVASTATIN CLINICAL EFFICACY AND SAFETY
by: V. V. Kukharchuk, et al.
Published: (2013-06-01)

EFFECTIVENESS OF ROSUVASTATIN IN VERY HIGH RISK CARDIOVASCULAR PATIENTS IN THE ACTUAL OUTPATIENT PRACTICE
by: V. P. Mikhin, et al.
Published: (2015-12-01)

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
by: VAVLUKIS ANA, et al.
Published: (2022-06-01)

Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
by: Colivicchi F, et al.
Published: (2015-11-01)

Pharmacological correction of experimental osteoporosis and fractures related to it by means of rosuvastatin, L-norvaline and their combination
by: Mikhail Sobolev, et al.
Published: (2018-12-01)

EFFECT OF ROSUVASTATIN ON CAROTID INTIMAMEDIA THICKNESS IN PATIENTS WITH CORONARY ARTERY DISEASE OF DIFFERENT GENDER AND CARDIOVASCULAR RISK PROFILE
by: S. I. Kononov, et al.
Published: (2018-05-01)

Clinical, lipid-lowering, and pleiotropic effectiveness of rosuvastatin: a review of the GALAXY programme results
by: A. N. Britov, et al.
Published: (2011-02-01)

Optimization of UPLC method for simultaneous determination of rosuvastatin and rosuvastatin degradation products
by: Jure Zakrajšek, et al.
Published: (2017-12-01)

Shenfu injection: a review of pharmacological effects on cardiovascular diseases
by: Fei-Fei Xu, et al.
Published: (2024-02-01)

Efficacy of Combination Therapy of Rosuvastatin and Ezetimibe vs Rosuvastatin Monotherapy on Lipid Profile of Patients with Coronary Artery Disease
by: Sandeep Joshi, et al.
Published: (2017-12-01)

Current perspectives on rosuvastatin
by: Hu M, et al.
Published: (2013-04-01)

Effect of rosuvastatin on repeat heart failure hospitalizations: the corona trial (controlled rosuvastatin multinational trial in heart failure)
by: Rogers, J, et al.
Published: (2014)

Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases
by: Nahida Srabović, et al.
Published: (2023-10-01)

Rosuvastatin safety and efficacy in coronary heart disease patients
by: I. V. Sergienko, et al.
Published: (2006-10-01)

Salvia miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications
by: Jie Ren, et al.
Published: (2019-07-01)

Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
by: Wang Z, et al.
Published: (2013-12-01)

Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
by: Vavlukis Ana, et al.
Published: (2023-09-01)

The Effect of Rosuvastatin on the Liver Enzyme of NMRI Mouse
by: Atena Nehzati Asl, et al.
Published: (2022-05-01)

Safety and vasopressor effect of rosuvastatin in septic patients
by: Hanaa A. El Gendy, et al.
Published: (2014-07-01)

Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
by: Ji Hoe Heo, et al.
Published: (2016-01-01)

Use of rosuvastatin to treat protease inhibitor-associated hypercholesterolaemia in a HIV-infected patient at high risk of cardiovascular diseases
by: Leonardo Calza
Published: (2010-09-01)

Perioperative rosuvastatin in cardiac surgery
by: Zheng, Z, et al.
Published: (2016)

Rosuvastatin-Induced reversible rhabdomyolysis
by: Sangeeta Pradhan, et al.
Published: (2023-01-01)

Rosuvastatin induced photolocalized purpura
by: Marwa Thabouti, et al.
Published: (2022-09-01)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
by: Gandhi SK, et al.
Published: (2012-01-01)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
by: Parson H
Published: (2010-01-01)

Rosuvastatin microcirculatory effects in patients with dyslipidemia and arterial hypertension
by: D. V. Nebieridze, et al.
Published: (2006-08-01)

Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats
by: Dilidaer Xilifu, et al.
Published: (2022-09-01)

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
by: Jun Sung Moon, et al.
Published: (2023-11-01)

SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE
by: E. V. Filippov, et al.
Published: (2015-12-01)

SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE
by: E. V. Filippov, et al.
Published: (2015-12-01)

Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial
by: Akintunde O. Akinkuolie, et al.
Published: (2016-07-01)

P1.07 ROSUVASTATIN INCREASES EXTRACELLULAR ADENOSINE IN HUMANS IN VIVO: A NEW PERSPECTIVE ON CARDIOVASCULAR PROTECTION
by: P. Meijer, et al.
Published: (2008-09-01)